---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-017858"
form_type: "8-K"
ticker: "INSM"
cik: "0001104506"
company_name: "INSMED Inc"
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T03:06:46.678748+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Insmed Q1 revenue up 23% to $92.8M; net loss widens to $1.42/sh; brensocatib PDUFA Aug 12

## Summary
- ARIKAYCE total revenue $92.8M (+23% YoY); FY2025 guidance reaffirmed $405-425M.
- Net loss $256.6M ($1.42/sh) vs $157.1M ($1.06/sh); R&D $152.6M, SG&A $147.5M.
- Brensocatib NDA accepted; PDUFA date Aug 12, 2025; EU/UK MAA accepted.
- TPIP Phase 2b in PAH completed; topline data expected June 2025; Phase 3 in PH-ILD planned H2 2025.
- $569.5M convertible notes redeemed; cash & securities $1.2B as of March 31.

## SEC filing metadata
- accession: 0001140361-25-017858
- form_type: 8-K
- ticker: INSM
- cik: 0001104506
- company_name: INSMED Inc
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1104506/000114036125017858/0001140361-25-017858-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1104506/000114036125017858/ef20048527_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-017858
- JSON: https://secwatch.observer/filing/0001140361-25-017858.json
- Plain text: https://secwatch.observer/filing/0001140361-25-017858.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.